Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy

Abstract

Cisplatin/pemetrexed chemotherapy has been established as a standard treatment in lung adenocarcinoma. However, the response to the cisplatin/pemetrexed combination varies considerably among patients due to individual variations. Thus, novel biomarkers are required to aid the prediction of the response to the cisplatin/pemetrexed combination. We hypothesized that leptin expression may be a determinant for prognosis in lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Serum from consenting patients with lung adenocarcinoma were obtained for the measurement of leptin and associated tumor biomarkers. Leptin expression was measured by radioimmunoassay. Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA15-3, CA125, CA72-4, cytokeratin 19 fragment (CYFRA21-1) and neuron-specific enolase (NSE) expression were determined by electrochemiluminescence immunoassays. Serum squamous cell carcinoma antigen levels were measured using a microparticle enzyme immunoassay. The associations between serum leptin and tumor biomarker expression were evaluated by Spearman’s correlation analysis. Serum CEA, CA19-9, CA15-3, CA125, CA72-4, CYFRA21-1 and NSE levels showed no obvious difference among patients. However, a trend towards an improved prognosis was observed in patients with lower serum leptin at diagnosis and an increase during cisplatin/pemetrexed chemotherapy. The results indicated that the serum leptin level has prognostic indications in patients with advanced lung adenocarcinoma during cisplatin/pemetrexed chemotherapy, which indicates that it may be a useful marker for the prognosis of cancer patients undergoing chemotherapy treatment.

Serum and tissue leptin in lung cancer: A meta-analysis

“…Ten of the 21 included articles were in English [13–18, 25, 29, 32, 33] and eleven were in Chinese [20, 21, 23, 24, 26, 28, 30, 31, 35–37]. Among the studies, fourteen articles were conducted in Chinese people [15, 18, 20, 21, 23, 24, 26, 28–31, 35–37], and seven studies were conducted in Europeans [13, 14, 16, 17, 25, 32, 33].…”

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

“…Several candidate predictive biomarkers including expression of thymidylate synthase, miR-25, miR-145, miR-210 and serum leptin have been studied but not sufficiently validated for the routine clinical use. [18][19][20][21] In this study, we focused on the association between TTF-1 expression and the efficacy of pemetrexed-based chemotherapy in patients with advancedstage non-squamous NSCLC.…”

Are serum leptin levels a prognostic factor in advanced lung cancer?

“…A study demonstrated that serum leptin has prognostic indica tions in patients with lung adenocarcinoma who are treated with cisplatin/pemetrexed chemotherapy in the fi rst-line setting (16). In another study, an interesting fi nding was that serum leptin levels showed a signifi cant effect on the overall survival of lung cancer patients.…”

“…However, leptin was reduced regardless of the response to chemotherapy and did not reach a statistical signifi cance (p = 0.06) in the study by Tas et al (13). In another study (16); the change in serum leptin levels were evaluated during chemotherapy. There was no statistically signifi cant difference pre-and post-chemotherapy.…”